SetPoint System Revolutionizes Rheumatoid Arthritis Treatment in North Carolina

On June 29, 2026, a significant milestone in medical technology was achieved when the SetPoint System® successfully treated its first patient in North Carolina, thanks to the collaboration between SetPoint Medical and the Arthritis & Osteoporosis Consultants of the Carolinas (AOCC). This landmark event underscores the potential of device-based therapies to enhance the treatment landscape for those battling rheumatoid arthritis (RA).

What is the SetPoint System?

The SetPoint System is an innovative FDA-approved therapy designed for adults suffering from moderately to severely active rheumatoid arthritis who have not experienced adequate relief from traditional biologic or targeted drug therapies. This system introduces a non-pharmacological solution, using a small implanted device that stimulates the vagus nerve. By activating the body's anti-inflammatory responses, it helps mitigate symptoms of RA, providing a groundbreaking alternative to conventional treatments.

Why is this Important?

Despite advancements in RA care, many patients endure ongoing symptoms and suffer the adversity of switching therapies in pursuit of relief. Dr. Gordon K.W. Lam, a rheumatologist at AOCC and part of the study investigating this therapy, highlighted that neuroimmune modulation could revolutionize treatment for these patients. "The SetPoint System utilizes the body's own neural pathways, presenting a fresh therapeutic approach. Our accomplishment in North Carolina shows promising progress in enhancing the well-being of individuals with RA," he stated.

As the largest independent rheumatology practice in the Southeast, AOCC plays a pivotal role in delivering innovative solutions. Dr. Ashley Toci, who referred the first patient for this system, emphasizes the importance of continuous collaboration among healthcare professionals to optimize patient care, stating that such partnerships are crucial in extending cutting-edge treatment options to those in need.

Evidence Supporting the Therapy

The clinical data garnered from the RESET-RA study revealed that patients utilizing the SetPoint System exhibited notable improvements in their disease activity, making a compelling case for its effectiveness in treating RA. The FDA's approval in 2025 marked a significant step towards providing patients with a much-needed solution that addresses both efficacy and tolerance concerns associated with traditional RA therapies.

Future Prospects

The launch of the SetPoint System in North Carolina is not merely a localized success; it symbolizes a broader movement toward embracing novel treatment modalities across the United States. Dr. Murthy Simhambhatla, CEO of SetPoint Medical, expressed enthusiasm about the therapy's expansion into North Carolina and highlighted the growing momentum of neuroimmune modulation treatments. He affirmed their commitment to developing partnerships with leading clinicians to reinforce the therapy's position as a reliable alternative to conventional drug treatments.

Looking ahead, the SetPoint Medical team is exploring expanding the application of their neurostimulation platform beyond rheumatoid arthritis, with plans to evaluate its potential in managing conditions such as multiple sclerosis and Crohn's disease. This ambitious vision reflects a dedication to redefining the management of autoimmune diseases.

Conclusion

In conclusion, the introduction of the SetPoint System in North Carolina is a pivotal development in the management of rheumatoid arthritis, offering renewed hope for patients who have struggled with inadequate treatment options. As innovative therapies like this gain traction, the future of RA treatment appears brighter, emphasizing the importance of collaborative efforts in advancing patient care and outcomes.